InflaRx N.V. · NASDAQ:IFRX

InflaRx — Leerink Partners Global Healthcare Conference 2022

39 slides from InflaRx's conference presentation, Feb 17, 2022

  1. Slide 1: Controlling Inflammation: Corporate Presentation

    CONTROLLING INFLAMMATION CORPORATE PRESENTATION February 2022

  2. Slide 2: Important Notice and Disclaimer

    IMPORTANT NOTICE AND DISCLAIMER This presentation has been prepared by InflaRx N.V. (“InflaRx”), a US-Nasdaq publicly listed Dutch company having its principal place of business in Germany. This presentation is made for informational purposes only and does not constitute an offer to sell or a solici

  3. Slide 3: InflaRx N.V.: Targeting Complement to Control Inflammatory Diseases

    InflaRx N.V. Targeting Complement to Control Inflammatory Diseases Lead product candidate entering pivotal testing, focus on immuno-dermatology Clinical Efficacy and Clean Safety Profile Enabling Vilobelimab to Advance in Multiple Indications • Hidradenitis Suppurativa (HS): Initiated pivotal Phase

  4. Slide 4: Pipeline with Multiple Opportunities

    Pipeline with Multiple Opportunities FRANCHISE INDICATIONS PRE-CLINICAL PHASE I PHASE II PHASE III UPDATE Hidradenitis • Pivotal trial initiated with new Suppurativa (HS) primary endpoint Immunodermatology Pyoderma • Positive Phase IIa open label Gangraenosum (PG) results Vilobelimab (IFX-1) • Phase

  5. Slide 5: The Terminal Complement Pathway

    The Terminal Complement Pathway C5 C5 concentration in blood: ~75 µg/ml (~400 nM) C5a concentration C5a C5b in blood: ~ 10 - 30 ng/ml strong amplifier Membrane Attack Complex (MAC) (~1-2.5 nM) of inflammation triggers lysis of pathogens activates C5b-9 = MAC Additional ligands: C5aR C5L2 C3a, ASP, C

  6. Slide 6: Vilobelimab Immunodermatology Focus

    I N N O VAT I O N TEAMWORK DISCOVERY COMPLEMENT Vilobelimab Immunodermatology Focus • Hidradenitis Suppurativa (HS) • Pyoderma Gangraenosum (PG)

  7. Slide 7: Hidradenitis Suppurativa (HS)

    Hidradenitis Suppurativa (HS) Debilitating C5a-driven inflammatory skin condition with high unmet need HURLEY STAGING FOR HS Stage I Clinical Features Single / multiple • Chronic, inflammatory, recurrent, debilitating skin disease of the hair follicles abscesses but no sinus • Most commonly in the a

  8. Slide 8: SHINE Phase II Study: Results and Conclusions

    SHINE Phase II Study Results and Conclusions RESULTS • HiSCR primary endpoint and dose response signal not met but signal towards improved AN count for the highest dose cohort • Statistically significant change in draining tunnels (dTs) and in ANdT count detected for the highest dose cohort • Pharma

  9. Slide 9: Current Status: Phase III Program Initiated in January

    Current Status: Phase III Program Initiated in January PHASE III STUDY INITIATED • Upon submission of study protocol for approval, InflaRx received no comments from FDA within 30-day and 60-day review periods. Thus, InflaRx expects no critical protocol review issues pending with FDA • Company initia

  10. Slide 10: Vilobelimab Phase III Trial in HS: Study Design

    Vilobelimab Phase III Trial in HS: Study Design Blinded Main Period Open Label Extension Period Placebo n=143 Vilobelimab (1600 mg q2w) n=286 Vilobelimab (1600 mg q2w) n=143 Screening & 16 weeks 38 weeks (34 weeks treatment + 4 weeks observation) Randomization Induction Treatment Treatment with 800m

  11. Slide 11: Vilobelimab Phase III Study in HS: Endpoints

    Vilobelimab Phase III Study in HS: Endpoints PRIMARY ENDPOINT (WEEK 16) modified Hidradenitis Suppurativa Clinical Response (m-HiSCR) Response defined as proportion of patients achieving both i. total body inflammatory lesion count (ANdT) reduction from baseline of at least 50% and ii. draining tunn

  12. Slide 12: Need for a New Primary Efficacy Endpoint: m-HiSCR

    Need for a New Primary Efficacy Endpoint in Actively Draining HS: Modified HiSCR (m-HiSCR) For a patient population suffering from dT, a score capturing dT reduction is needed Modified HiSCR: a. Considers reduction of all 3 inflammatory lesions b. Emphasizes reduction of draining tunnels c. Anticipa

  13. Slide 13: The New m-HiSCR as Primary Endpoint

    The New Modified (m-)HiSCR as Primary Endpoint is a Responder Score which is Based on All Three Inflammatory Lesions in HS Inflammatory Lesions (assessed by physician) HiSCR N= A+N total number of m-HiSCR ≥ 50% AN inflam. nodules count reduction ≥ 50% ANdT rel. to baseline A= ANdT count reduction AN

  14. Slide 14: SHINE Study: m-HiSCR Responders

    SHINE Study: m-HiSCR Responders in Moderate to Severe HS with at least one dT (Relative to Baseline, at least 50% Reduction of ANdT Count with 50% Reduction of dT Count) m-HiSCR response rate at Week 16* 60 p= 0.0424 54,5 • In SHINE, significant reduction of dT count only achieved with high dose (as

  15. Slide 15: SHINE Study: Open Label Extension m-HiSCR Response

    SHINE Study: Open Label Extension Period – m-HiSCR Response Patients group categorized according to m-HiSCR response at end of main phase* 100 m-HiSCR responder (%) 80 Total m-HiSCR responder at week 16 60 40 Total m-HiSCR non-responder at week 16 20 0 16 24 32 40 week 38 33 32 n 77 55 50 Total m-Hi

  16. Slide 16: SHINE OLE: Placebo and High-dose Group m-HiSCR Responses

    SHINE Open Label Extension Period – Placebo and High-dose Group m-HiSCR Responses m-HiSCR response* 80 60 m-HiSCR response (%) Original high-dose group 40 Original placebo group 20 0 16 24 32 40 week 22 17 16 n 23 19 19 Original placebo group Original high-dose group (1200mg Q2W) Although suboptimal

  17. Slide 17: The Extended e-m-HiSCR Secondary Endpoint

    The Extended (e)-m-HiSCR is a Secondary Endpoint: Adding 1 Additional Criterion to m-HiSCR Primary Endpoint Secondary Endpoint • e-m-HiSCR introduced as secondary endpoint based on m-HiSCR e-m-HiSCR recommendation of FDA to include the aspect of no ≥ 50% ANdT ≥ 50% ANdT increase in absesses from bas

  18. Slide 18: Pyoderma Gangraenosum (PG)

    Pyoderma Gangraenosum (PG) AN AUTOIMMUNE CONDITION WITH HIGH UNMET NEED Clinical Features • PG is a rare but potentially life-threatening skin disorder that can lead to chronic, highly painful and difficult-to-treat wounds • Many PG patients also suffer from other autoimmune disorders, such as ulcer

  19. Slide 19: PG Phase IIa Study Design

    PG Phase IIa Study Design • 19 patients enrolled in the study • Primary endpoint: Safety • Key secondary endpoints: Responder rate defined as PGA ≤3 (PGA of ≤1 is considered clinical remission and closure of target ulcer); Time to complete closure of target ulcer INITIATION MAINTENANCE INDIVIDUAL TI

  20. Slide 20: Study Results – Group 1 (Low Dose)

    Study Results – Group 1 (Low Dose) PGA-line plot of absolute values over time by patient (Actual days displayed acc. to visit windows) PGA Six evaluable 01 03 05 score subjects: 02 04 06 GROUP 1 RESULTS • Two patients (02 and 05) achieved complete remission of target ulcer * • One patient (01) with

  21. Slide 21: Study Results – Group 2 (Medium Dose)

    Study Results – Group 2 (Medium Dose) PGA-line plot of absolute values over time by patient (Actual days displayed acc. to visit windows) PGA Four evaluable 07 09 11 score patients: 08 10 12 GROUP 2 RESULTS • One patient (10) out of four healed upon up-titration to ** 2400mg group on day 57 with PGA

  22. Slide 22: Study Results – Group 3 (High Dose)

    Study Results – Group 3 (High Dose) PGA-line plot of absolute values over time by patient (Actual days displayed acc. to visit windows) PGA Seven evaluable 13 * 15 17 19 score patient: 14 16 18 GROUP 3 RESULTS • Six patients out of 7 achieved PGA score of ≤ 1 (remission) • One patient (18) experienc

  23. Slide 23: PG Phase IIa Patient Case Study

    PG Phase IIa Patient 10 Case Study TARGET ULCER REAPPEARED IN AUGUST 2020 MH: PG since Jun 2019, Hypertension since 1998; Study Day 1: Feb 2021 Cohort 2: 1600 mg Q2W, individual uptitration to 2400 mg at D57, treatment completed Previous PG medication: Methylprednisolone only in Jun 2019, Dapsone Ju

  24. Slide 24: PG Phase IIa Patient Case Study

    PG Phase IIa Patient 14 Case Study PG TREATMENT HISTORY: CICLOSPORIN, DAPSONE MH: PG since October 2018, Obesity since longer time (no exact day available) Treatment Start: February 2021 Cohort 3: 2400 mg Q2W treatment completed Previous PG medication: Ciclosporin and methylprednisolone October 2018

  25. Slide 25: PG Phase IIa Patient Case Study

    PG Phase IIa Patient 13 Case Study TARGET ULCER OPENED IN NOVEMBER 2020 WHILE ON STABLE ADALIMUMAB MH: PG since August 2020, Psoriasis since 2017 Treatment Start: March 2021 Previous PG medication: None Cohort 3: 2400 mg Q2W up to Day 85 → exclusion after 9 doses due to delayed availability of pos.

  26. Slide 26: PG Phase IIa Study Results: Summary and Conclusion

    PG Phase IIa Study Results Summary and Conclusion SAFETY CONCLUSION • No infusion-related reactions observed • For 2 patients, related SAEs were reported: • Erysipelas leading to hospitalization (judged as non-related by sponsor) • Rash due to delayed hypersensitivity reaction WE WILL MEET • Observe

  27. Slide 27: Vilobelimab Life-threatening Inflammatory Diseases

    I N N O VAT I O N TEAMWORK DISCOVERY COMPLEMENT Vilobelimab Life-threatening Inflammatory Diseases • COVID-19 • ANCA Associated Vasculitis (AAV)

  28. Slide 28: COVID-19 induced Vascular Injury – Potential Role of C5a

    COVID-19 induced Vascular Injury – Potential Role of C5a Model for Proposed Mode of Action of C5a in COVID-19 induced vascular injury OUR HYPOTHESIS • Endothelial damage is induced by SARS-CoV-2 infection which also activates the complement system leading to C5a generation. • C5a activates neutrophi

  29. Slide 29: Phase II Part Results

    Phase II Part Results Overview PHASE II STUDY RESULTS* Primary endpoint: • No difference detected in improvements between groups in PaO2/FiO2 ratio • High variability between patients • Conclusion: Endpoint not suitable as response parameter Key secondary and other endpoints - Observed effects with

  30. Slide 30: Design of Phase II/III Study in Severe COVID-19

    Design of Phase II/III Study with Vilobelimab in Severe COVID-19 Open-label 800mg i.v. STUDY DESIGN Phase II Vilobelimab + BSC • Critically ill intubated* patients with COVID-19 Part 28 days (n=15) induced pneumonia COMPLETED Best supportive care Dosing scheme: • Phase III primary endpoint: 28-day a

  31. Slide 31: Phase II Studies in AAV: Results

    Phase II Studies in AAV Results EU PHASE II TOPLINE RESULTS (N=57 TOTAL) • Demonstrated Proof of concept for vilobelimab to reduce use of glucocorticoid (GC) therapy in AAV • Achieved comparable efficacy to standard of care GC therapy • Use of vilobelimab instead of GC led to a substantially lower o

  32. Slide 32: Vilobelimab Oncology

    I N N O VAT I O N TEAMWORK DISCOVERY COMPLEMENT Vilobelimab Oncology • Cutaneous Squamous Cell Carcinoma (cSCC)

  33. Slide 33: Cutaneous Squamous Cell Carcinoma (cSCC)

    Cutaneous Squamous Cell Carcinoma (cSCC) Phase II Study Underway POTENTIAL ROLE OF C5A IN ONCOLOGY & cSCC DISEASE INFORMATION cSCC • C5a induces an immunosuppressive tumor microenvironment • Estimated incidence: 15-35 per 100,000 people; expected to • C5a promotes metastases increase 2-4% per year;

  34. Slide 34: INF904 New Pipeline Program

    I N N O VAT I O N TEAMWORK DISCOVERY COMPLEMENT INF904 New Pipeline Program

  35. Slide 35: Background: C5aR and its allosteric inhibitor INF904

    Background C5aR and its allosteric inhibitor INF904 C5a and INF904 Nathan Robertson, 2018 Nature • C5a receptor (C5aR): Heng Liu, 2018, Nat. Struct. Mol. Biol • a 7-transmembrane G-protein-coupled-receptor C5a expressed primarily on granulocytes, mediates the major pathophysiological effects of C5a

  36. Slide 36: INF904: Potential for Best in Class C5aR Inhibition

    INF904 Potential for Best in Class C5aR Inhibition Neutropenia in vivo Model PROGRAM DETAILS ✱✱ Avacopan-like 120 (10mg/kg oral) • INF904 shows no obvious toxicological findings even in the highest dose 100 INF904 % Inhibition 80 (10mg/kg oral) groups in required GLP toxicity analyses Vehicle 60 • I

  37. Slide 37: Strategy and Outlook

    I N N O VAT I O N TEAMWORK DISCOVERY COMPLEMENT Strategy and Outlook

  38. Slide 38: Strategic Objectives

    Strategic Objectives Immuno- • HS: Initiate Phase III program with vilobelimab, incorporating novel endpoint dermatology • PG: Advance vilobelimab towards Phase III based on regulatory guidance Focus • Severe COVID-19: Complete Phase III with vilobelimab; Submit for approval if results are positive

  39. Slide 39: InflaRx N.V. Investor Relations

    INFLARX N.V. INVESTOR RELATIONS INFLARX N.V. Winzerlaer Str. 2 Jordan Zwick 07745 Jena, Germany Chief Strategy Officer Email: [email protected] Email: [email protected] Tel: +49-3641-508180 Fax: +49-3641-508181 www.inflarx.com

InflaRx — Leerink Partners Global Healthcare Conference 2022 on 6ix